AbCellera Biologics (ABCL) News Today $3.14 +0.03 (+0.80%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash BurnJune 13, 2025 | seekingalpha.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Should You Sell?AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - What's Next?June 13, 2025 | marketbeat.comInvestors Buy High Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)June 13, 2025 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Time to Buy?AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Should You Buy?June 11, 2025 | marketbeat.comAbCellera Biologics Target of Unusually High Options Trading (NASDAQ:ABCL)AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors purchased 8,562 call options on the stock. This is an increase of approximately 1,191% compared to the average volume of 663 call options.June 11, 2025 | marketbeat.comAbCellera Biologics Inc. (ABCL): A Bull Case TheoryJune 10, 2025 | finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.6% - Should You Buy?AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.6% - Time to Buy?June 10, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.9% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.9% - Still a Buy?June 4, 2025 | marketbeat.comWhy AbCellera Biologics Stock Raced Nearly 6% Higher TodayJune 2, 2025 | fool.comAbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic DermatitisMay 31, 2025 | insidermonkey.comAbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLCMillennium Management LLC raised its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 96.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,482,715 shares of the company's stock after purchaMay 31, 2025 | marketbeat.comAbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575May 30, 2025 | businesswire.comTwo Sigma Investments LP Increases Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Two Sigma Investments LP raised its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 28.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,257,311 shares of the company's stocMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Buys 430,800 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Two Sigma Advisers LP grew its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,608,400 shares of the company's stock after puMay 26, 2025 | marketbeat.comAbCellera Biologics Inc. (ABCL): Analysts See 474% Upside PotentialMay 21, 2025 | insidermonkey.comTang Capital Management LLC Grows Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Tang Capital Management LLC grew its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,582,816 shares of the company's stock after buying an additional 2May 20, 2025 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Lazard Asset Management LLCLazard Asset Management LLC trimmed its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 15.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 928,594 shares of the company's stock afterMay 19, 2025 | marketbeat.comTruist Financial Remains a Buy on AbCellera Biologics (ABCL)May 18, 2025 | theglobeandmail.comAbCellera Biologics Inc. (NASDAQ:ABCL) is Prosight Management LP's 5th Largest PositionProsight Management LP lessened its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,350,000 shares of the company's stock after sellingMay 17, 2025 | marketbeat.comAnalyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL)May 16, 2025 | uk.finance.yahoo.comAbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to MenopauseMay 14, 2025 | businesswire.comAbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal CircuitMay 12, 2025 | finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Announces Earnings ResultsAbCellera Biologics (NASDAQ:ABCL - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The firm had revenue of $4.24 million during the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%.May 11, 2025 | marketbeat.comAbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual MeetingMay 9, 2025 | businesswire.comAbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025May 9, 2025 | msn.comAbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAbCellera Biologics Inc. 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comAbCellera Biologics Q1 2025 Earnings PreviewMay 8, 2025 | msn.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 6.8% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.8% - Here's What HappenedMay 7, 2025 | marketbeat.comAbCellera Biologics (ABCL) Projected to Post Quarterly Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-abcellera-biologics-inc-stock/)May 3, 2025 | marketbeat.comWalleye Capital LLC Reduces Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Walleye Capital LLC lowered its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 94.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,000 shares of the company's stock after selling 241,881 shares during the quarter. WalleyeApril 30, 2025 | marketbeat.comAbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025April 29, 2025 | businesswire.comAbCellera Biologics Inc. (NASDAQ:ABCL) Stock Position Decreased by TD Waterhouse Canada Inc.TD Waterhouse Canada Inc. lowered its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 55.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 104,594 shares of the company's stock after selling 1April 28, 2025 | marketbeat.comCapital World Investors Takes Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Capital World Investors acquired a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 7,933,613 shares of the company's stock, valued at approximately $23,245,000. Capital WoApril 24, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Time to Sell?AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's What HappenedApril 23, 2025 | marketbeat.comIs AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?April 23, 2025 | msn.comPeak6 LLC Makes New Investment in AbCellera Biologics Inc. (NASDAQ:ABCL)Peak6 LLC acquired a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 199,995 shares of the company's stock, valued at approximately $586,000. Peak6 LLC owned approximately 0.07April 23, 2025 | marketbeat.comRenaissance Technologies LLC Sells 459,810 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Renaissance Technologies LLC trimmed its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,486,893 shares of the company'sApril 21, 2025 | marketbeat.comBrokers Set Expectations for ABCL Q1 EarningsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Leerink Partnrs issued their Q1 2026 earnings estimates for AbCellera Biologics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.16) per share forApril 20, 2025 | marketbeat.comLeerink Partners Remains a Buy on AbCellera Biologics (ABCL)April 19, 2025 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Given New $5.00 Price Target at KeyCorpKeyCorp raised their target price on AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday.April 18, 2025 | marketbeat.comAbCellera price target raised to $5 from $4 at KeyBancApril 17, 2025 | markets.businessinsider.comAbCellera: Attractively Priced But A Catalyst Is NeededApril 16, 2025 | seekingalpha.comKeyBanc Remains a Buy on AbCellera Biologics (ABCL)April 16, 2025 | theglobeandmail.comFederated Hermes Inc. Lowers Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Federated Hermes Inc. reduced its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 59.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 916,237 shares of the company's stock after selApril 15, 2025 | marketbeat.com281,795 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 281,795 shares of the company's stock, valued atApril 13, 2025 | marketbeat.com1,284,533 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by Norges BankNorges Bank bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,284,533 shares of the company's stock, valued at approximately $3,764,000. Norges Bank owned aApril 13, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low - Should You Sell?AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.comAbCellera to Participate at Upcoming Investor Conferences in May and JuneApril 8, 2025 | financialpost.comAbCellera Biologics (NASDAQ:ABCL) Shares Up 5.9% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Trading 5.9% Higher - Should You Buy?April 4, 2025 | marketbeat.com Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Media Mentions By Week ABCL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.680.56▲Average Medical News Sentiment ABCL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼63▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACADIA Pharmaceuticals News Today Merus News Today Avidity Biosciences News Today Arcellx News Today SpringWorks Therapeutics News Today Ultragenyx Pharmaceutical News Today Protagonist Therapeutics News Today Scholar Rock News Today Kymera Therapeutics News Today Viking Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts